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Troponin
Messenger or Actor?
Richard L. Popp, MD
Stanford, California
Cardiac troponin (cTn) is a biomarker of myocardial damage. New generations of high-sensitivity assays find cir-
culating cTn in virtually all subjects. Multiple studies in various populations and patient groups have found higher
levels of cTn to be predictive of future heart failure. The author proposes that initial myocardial damage from
various mechanisms may lead to anti-cTn antibodies that participate in ongoing myocardial damage that eventu-
ally results in heart failure. (J Am Coll Cardiol 2013;61:611–4) © 2013 by the American College of Cardiology
Foundation
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The recent publication of the “Third Universal Definition of
Myocardial Infarction” (MI) is a major step in redefinition
of clinical entities of great clinical interest (1). It states,
“Myocardial injury is detected when blood levels of sensitive
and specific biomarkers such as cTn [cardiac troponin] or
the MB fraction of creatine kinase (CKMB) are increased.
Cardiac troponin I and T are components of the contractile
apparatus of myocardial cells and are expressed almost
exclusively in the heart. Although elevations of these bio-
markers in the blood reflect injury leading to necrosis of
myocardial cells, they do not indicate the underlying mech-
anism.” This comprehensive statement sets out prototypes
of coronary pathophysiology as the basis for MI, and it relies
on serial measurements of cTn in association with clinical
presentation and other features for the updated definition of
MI in various circumstances. Acute or stuttering myocellu-
lar necrosis has been the model for our interpretation of
levels of cTn measured in the circulation. Measurements of
this biomarker have evolved over the past several years in
parallel with further understanding of the dynamics of cTn
release.
The appearance of detectable cTn alerted us to myocar-
dial damage when we could detect such levels only in
pathologic states. However, the newest technologies for
high-sensitivity and ultra-high-sensitivity measurement of
cTn reveal detectable levels of these proteins and their
components in 66% to 100% of patients or subjects (2–4).
This new level of detection not only dictates re-evaluation of
the threshold and time course of change in cTn for the
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something important. Assessing the level of cTn may be a
tool to better understand the path from normal myocardial
function to clinical states we eventually see as heart failure.
The published research is a bit confusing for the physi-
cian not conversant with the specific techniques used for
measurements of cTn, which are noted usually only in the
“Methods” sections of reports. The reports in this evolving
field include measurements of cTn using systems with
various sensitivities (5). These are sometimes termed “third-
generation systems” or “fourth-generation systems.” The
systems are characterized by 2 parameters that clinicians
should be aware of: the level of 10% coefficient of variation
(CV) and the 99th percentile level of concentration for a
normal population. The former is determined by repeated
measurement of samples of known concentrations of the
substance being analyzed. At high concentrations, the
repeated measurement “wobbles” by a small percent. At
some point with lower and lower concentrations, the CV of
the repeated measurement reaches at least 10%. At or below
this absolute level of concentration, the measurement is
considered too variable for reliable use. Early systems for
measuring cTn had a 10% CV near 100 pg/ml. Third-
generation systems have a 10% CV near 40 pg/ml, so
third-generation measurement of an asymptomatic popula-
tion can reliably characterize cTn circulating at 40 to 50
pg/ml. These systems have been used to assess asymptom-
atic or “normal” populations, finding that 99% of subjects
had cTn levels less than about 50 pg/ml. The current
fourth-generation immunoassay systems have a 10% CV
near 1 pg/ml. Troponin is found in 100% of normal subjects
with these systems, but 99% of the subjects considered
normal have levels 10 pg/ml (4). The 99th percentile
levels used for comparison with study populations men-
tioned in this report are derived from groups considered not
to have cardiovascular disease.
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Troponin: Messenger or Actor? February 12, 2013:611–4Elevations of cTn are consid-
ered by the authors of the “Third
Universal Definition of Myocardial
Infarction” to be an expression of
“myocardial injury” due to: 1) pri-
mary myocardial ischemia; 2) sup-
ply-demand imbalance of myocar-
dial ischemia; 3) injury not related
o myocardial ischemia (generally involving myocardial trauma or
oxic agents); and 4) multifactorial or indeterminate myocardial
njury (1). Integral to the recent redefinition of MI is acknowl-
dgment of the ongoing detectable level of cTn already present
n patients in the setting of chronic heart failure, after noncar-
iac surgery, those with renal failure, and otherwise.
Primary myocardial ischemia is considered the predomi-
ant mechanism for MI and myocellular necrosis. However,
ime-varying elevations of cTn also occur in cases of
upraventricular tachycardia, pulmonary embolism and after
oncardiac surgery (6). These observations have been attrib-
ted to supply-demand imbalance. However, levels of cTn
lso appear elevated in settings of myocarditis, cardiac
rauma, cancer chemotherapy, renal failure, rheumatoid
rthritis, supraventricular tachycardia, pulmonary hyperten-
ion, stroke, and subarachnoid hemorrhage (6).
White (7) suggested 6 mechanisms of “pathobiology of
roponin elevations”: 1) myocyte necrosis; 2) apoptosis; 3)
ormal myocyte turnover; 4) cellular release of proteolytic
roponin degradation products; 5) increased cell wall per-
eability; and 6) formation and release of membranous
lebs. There is evidence for the development and (probable)
elease of membranous “blebs” from ischemic myocytes in
issue culture, so disruption of cell membranes may not be
ecessary for the release of cTn into the circulation (8). Such
leb formation might be a mechanism for cTn elevation
uring reversible ischemia without necrosis. But what
hould we think of the ongoing cTn elevations seen in the
bsence of detectible ischemia?
In some cases, our inability to detect ischemia with
urrent clinical methods may mask the classic paradigm as a
ause of increased levels of such biomarkers. Elevation of
Tn was attributed to “silent ischemia” in one study in
hich electrocardiographic ST-segment depression was
onitored and found to be associated with cTn levels (9). A
urprisingly high percent of post-operative patients under-
oing noncardiac surgery have elevated cTn in absolute
erms or as a change from baseline levels. Kavsak et al. (10)
ound that 45% of patients undergoing noncardiac surgery
ad elevated cTn levels (over the published 99th percentile
f the normal population), and 22% had changes (85%) in
Tn levels from their preoperative baseline levels. They
oted that the optimal level of cTn for diagnosis of MI may
eed further definition in this and other populations.
aseline levels of cTn are a factor complicating the current
efinition of post-operative MI (1). It may be assumed that
here is a stress-induced supply-demand imbalance leading
Abbreviations
and Acronyms
cTn  cardiac troponin
CV  coefficient of
variation
MI  myocardial infarctiono ischemic myocardial damage during and after surgery, but wbout half of these patients with biomarker evidence of
yocardial ischemia or necrosis have no other evidence of
yocardial damage (10). In the VISION (Vascular Events
n Noncardiac Surgery Patients Cohort Evaluation) study of
atients undergoing noncardiac surgery, cTn was measured
ith a high-sensitivity assay over the first 3 days after
urgery. Levels of cTn elevation showed a graduated rela-
ionship to mortality at 30 days (11). Another study of
atients after noncardiac surgery using meta-analysis asso-
iated elevated cTn with mortality at 12 months (12). These
tudies make one wonder what ongoing biologic event(s)
he biomarker is indicating. If there is ongoing myocellular
schemia, then this mechanism leading to death and/or the
linical syndromes of heart failure is more prominent,
ccult, and ongoing than most have suspected.
evels of Troponin as a Risk Factor
n this context, it is especially interesting that stratifying the
ontinuum of levels of cTn in various populations has
hown prognostic significance for higher strata of cTn for
he future development and course of heart failure and
ortality but less prognostication for future coronary events
2,3,13–21). The lack of prognostic value of cTn for future
oronary events despite the link to future heart failure
uggests that myocardial or myocellular damage is occur-
ing, but it is not necessarily aligned with our concepts of
ngoing coronary artery disease–based “ischemia.” In some
ases, a chronic imbalance between myocardial demand and
oronary microcirculation supply may be present. Cardiac
roponin levels in asymptomatic subjects are associated with
uture development of heart failure in several well-done
opulation studies. The Dallas Heart Study of 3,546 asymp-
omatic subjects placed them into 5 categories on the basis
f cTn levels. High-sensitivity assays detected levels at or
bove the 99th percentile in one-quarter of the subjects
fter 6 years there was a relationship between cTn level and
eath. The investigators stated, “After adjusting for tradi-
ional risk factors, C-reactive protein level, chronic kidney
isease, and N-terminal pro-brain-type natriuretic peptide,
TnT category remained independently associated with
ll-cause mortality” (15).
In the Minnesota Heart Survey, “seven biomarkers were
ssayed in serum samples from 211 patients identified after
to 15 years of follow-up who died of cardiovascular
auses,” compared with 253 matched controls. The investi-
ators concluded, “cTnI is a key biomarker associated with
ncreased cardiovascular death in a community sample when
valuated in a multiple biomarker analysis” (18). Wang et al.
19) looked at 3 “novel biomarkers induced by cardiovascu-
ar stress,” including cTnI, to potentially improve prognostic
nformation in 3,428 members of the Framingham Heart
tudy community. After a mean follow-up period of 11.3
ears, each of the biomarkers was associated with deaths,
ajor cardiovascular events, and heart failure events but not
ith coronary events.
613JACC Vol. 61, No. 6, 2013 Popp
February 12, 2013:611–4 Troponin: Messenger or Actor?Troponin may be a messenger of subclinical cardiovascu-
lar changes. A prospective study of 300 asymptomatic
subjects already on primary cardiovascular disease preven-
tion measures and studied by imaging methods revealed
“silent cardiac target organ damage” such as myocardial
ischemia, left ventricular hypertrophy, systolic dysfunction,
diastolic dysfunction, or left atrial enlargement already
present in 34% of subjects. Combining levels of B-type
natriuretic peptide and cTnT performed best in identifying
these cases (20). Ongoing levels of myocardial damage or
stress are also noted in patients already in heart failure.
During routine follow-up of patients already under therapy
for heart failure, serial changes in cTn categorized their risk
for progression, death, or cardiac transplantation (3,21).
The pathologic physiology in such patients is complex, but
it is interesting to consider what mechanisms of ongoing
myocardial damage may be operating in addition to, or
instead of, myocardial ischemia as we usually conceive it.
The elevation of cTn in patients receiving certain cancer
chemotherapeutic agents is almost surely due to direct toxic
effects of these drugs on the myocardium (5). Cardiac
troponin is elevated in patients with renal failure as well as
in those with sepsis (5). Some of these situations may fit the
definition of supply-demand imbalance alone as noted
earlier. However, in these conditions, there might be other
circulating toxins injurious to the myocardium as well.
Another potential agent of myocardial injury was suggested
in an analysis of material from the ARIC (Atherosclerosis
Risk in Communities) study (22). The investigators looked
at glycemic state, measured by glycosylated hemoglobin, and
subclinical myocardial injury, signaled by elevations in
cTnT, in subjects without clinically evident coronary heart
disease. The graded increasing levels of glycosylated hemo-
globin associated with elevated cTnT suggested “that hy-
perglycemia contributes to myocardial injury beyond its
effects on development of clinical atherosclerotic coronary
disease.”
Autoimmunity
Mouse studies have shown that the induction of anti-cTnI
antibodies can lead to myocardial inflammation, followed by
cardiomegaly, fibrosis, and reduced long-term survival (23).
Kaya et al. (24) reported that transfer of cTn-specific T cells
can induce inflammation and fibrosis in wild-type mice,
leading to contractile dysfunction, and they identified 2
sequence motifs of cTnI that are specific for this effect.
Leuschner et al. (25) found that patients after MI with
anti-cTn antibodies failed to show the improvements in left
ventricular ejection fraction and stroke volume seen in
antibody-negative patients at 6 to 9 months after MI.
Pettersson et al. (26) followed patients after acute coronary
syndromes, finding that those presenting with, or later
developing, autoantibodies to cTn had significantly in-
creased autoantibodies at 1 week and at 3 months and
persistent cTn elevations at 3 months and at 1 yearcompared with those without these antibodies. A mouse
model of ischemia-reperfusion injury was compared with
coronary occlusion without reperfusion regarding the effect
of autoantibodies to cTnI. Ongoing myocardial inflamma-
tion and cardiac dysfunction detectable as late at 6 months
after MI occurred in both groups with autoantibodies.
However, those with reperfusion showed higher inflamma-
tion scores compared with those with occlusion alone (27).
Circulating autoantibodies to cTn are present in patients
with idiopathic dilated cardiomyopathy. Although higher
levels of cTn are associated with worse clinical parameters,
the presence of antibodies to cTn was not associated with
patients’ clinical status or prognosis (28).
One may hypothesize that autoimmune mechanisms are
involved after clinical events leading from initial myocardial
injury to chronic ongoing myocardial damage. The models
of multiple sclerosis and rheumatoid arthritis show that
there is precedent for such biology. The cause of the initial
myocardial damage might be acute ischemia with infarction,
reversible ischemia, supply-demand imbalance ischemia,
trauma, or toxic agents. Depending on the magnitude of the
damage, and perhaps the time course of the insult, as well as
genetic predisposition to the immunologic response, auto-
antibodies may be formed. The possibility of troponin
autoantibodies as an agent of myocellular damage has been
validated by the German and Finnish studies noted earlier
(23–27). Autoantibodies then might contribute to an in-
flammatory process accounting for the further chronic
deterioration in myocardial function that finally results in
the syndrome of heart failure. It is possible that cTn per se
is the focus of this immune response, but also it may be only
one marker of myocardial damage that is primary and
ongoing, with other antigens the focus of the immune
response as well.
It is generally true that a process can only be understood
when that process can be well measured. The ability to
reliably measure cTn and antibodies to cTn with current
levels of sensitivity is pointing us toward new questions
regarding the paths from myocardial health to myocardial
damage and eventually to the clinical syndromes of heart
failure. The detectable levels of cTn in patients and popu-
lations should be a stimulus to look into these mechanisms
further. It would be fascinating if cTn is proved to be an
actor in this process of ongoing myocardial injury and not
simply a messenger of that injury.
Reprint requests and correspondence: Dr. Richard L. Popp,
Room E-100-D, The James H. Clark Center, 318 Campus Drive
West, Stanford, California 94305. E-mail: rich.popp@gmail.com.
REFERENCES
1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White
HD. Third universal definition of myocardial infarction. Circulation.
Available at: http://circ.ahajournals.org/content/early/2012/08/23/
CIR.0b013e31826e1058.citation. Accessed December 7, 2012.
11
1
2
2
2
2
2
2
2
2
2
614 Popp JACC Vol. 61, No. 6, 2013
Troponin: Messenger or Actor? February 12, 2013:611–42. Omland T, deLemos JA, Sabatine MS, et al. A sensitive cardiac
troponin T assay in stable coronary artery disease. N Engl J Med
2009;361:2538–47.
3. Latini R, Masson S, Anand IS, et al., for the Val-HeFT Investigators.
Prognostic value of very low plasma concentrations of troponin T in
patients with stable chronic heart failure. Circulation 2007;116:
1242–9.
4. Apple FS, Simpson PA, Murakami MM. Defining the serum 99th
percentile in a normal reference population measured by a high-
sensitivity cardiac troponin I assay. Clin Biochem 2010;43:1034–6.
5. Keller T, Munzel T, Blankenberg S. Making it more sensitive: the new
era of troponin use. Circulation 2011;123:1361–3.
6. Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in
coronary vs. non-coronary disease Eur Heart J 2011;32:404–11.
7. White HD. Pathobiology of troponin elevations: do elevations occur
with myocardial ischemia as well as necrosis? J Am Coll Cardiol
2011;57:2406–8.
8. Hickman PE, Potter JM, Aroney C, et al. Cardiac troponin may be
released by ischemia alone, without necrosis. Clin Chim Acta 2010;
411:318–23.
9. Shah AS, Langrish JP, Li X, Jiang L, Newby DE, Mills NL. Cardiac
troponin reflects silent myocardial ischemia in patients with stable
coronary artery disease. J Am Coll Cardiol 2012;59:E1415.
10. Kavsak PA, Walsh M, Srinathan S, et al. High sensitivity troponin T
concentrations in patients undergoing noncardiac surgery: a prospec-
tive cohort study. Clin Biochem 2011;44:1021–4.
11. Devereaux PJ, for the VISION Writing Group. Association between
postoperative troponin levels and 30-day mortality among patients
undergoing noncardiac surgery. JAMA 2012;307:2295–304.
12. Levy M, Heels-Ansdell D, Hiralal R, et al. Prognostic value of
troponin and creatine kinase muscle and brain isoenzyme measure-
ment after noncardiac surgery: a systematic review and meta-analysis
Anesthesiology 2011;114:796–806.
13. Sundstrom J, Ingelsson E, Berglund L, et al. Cardiac troponin-I and
risk of heart failure: a community-based cohort study. Eur Heart J
2009;30:773–81.
14. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of
serial measures of cardiac troponin T using a sensitive assay with
incident heart failure and cardiovascular mortality in older adults.
JAMA 2010;304:2494–502.
15. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin
T detected with a highly sensitive assay and cardiac structure and
mortality risk in the general population. JAMA 2010;304:2503–12.16. Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T
measured by a highly sensitive assay predicts coronary heart disease,heart failure, and mortality in the Atherosclerosis Risk in
Communities study. Circulation 2011;123:1367–76.
7. Eggers K, Lagerqvist B, Venge P, Wallentin L, Lindahl B. Persistent
cardiac troponin I elevation in stabilized patients after an episode of
acute coronary syndrome predicts long-term mortality. Circulation
2007;116:1907–14.
8. Apple F, Steffen LM, Pearce LA, Murakami MM, Luepker RV.
Increased cardiac troponin I as measured by a high-sensitivity assay is
associated with high odds of cardiovascular death: the Minnesota
Heart Survey. Clin Chem 2012;58:930–5.
9. Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel
biomarkers of cardiovascular stress: the Framingham Heart Study.
Circulation 2012;126:1596–604.
0. Nadir MA, Rekhraj S, Wei L, et al. Improving primary prevention of
cardiovascular events by using biomarkers to identify individuals with
silent heart disease. J Am Coll Cardiol 2012;60:960–8.
1. Miller WL, Hartman KA, Burritt MF, Grill DE, Jaffe AS. Profiles of
serial changes in cardiac troponin T concentrations and outcome in
ambulatory patients with chronic heart failure. J Am Coll Cardiol
2009;54:1715–21.
2. Rubin J, Matsushita K, Ballantyne CM, Hoogeveen R, Coresh J,
Selvin E. Chronic hyperglycemia and subclinical myocardial injury.
J Am Coll Cardiol 2012;59:484–9.
3. Goser S, Andrassy M, Buss SJ, et al. Cardiac troponin I but not cardiac
troponin T induces severe autoimmune inflammation in the myocar-
dium. Circulation 2006;114:1693–702.
4. Kaya Z, Goser S, Buss SJ, et al. Identification of cardiac troponin I
sequence motifs leading to heart failure in induction of myocardial
inflammation and fibrosis. Circulation 2008;118:2063–72.
5. Leuschner F, Li J, Goser S, et al. Absence of auto-antibodies against
cardiac troponin I predicts improvement of left ventricular function
after acute myocardial infarction. Eur Heart J 2008;29:1949–55.
6. Pettersson K, Eriksson S, Wittfooth S, Engstrom E, Nieminen M,
Sinisalo J. Autoantibodies to cardiac troponin associate with higher
initial concentrations and longer release of troponin I in acute coronary
syndrome patients. Clin Chem 2009;55:938–45.
7. Volz CH, Buss SJ, Li J, et al. Autoimmunity against troponin I in
ischaemia reperfusion injury. Eur J Heart Fail 2011;13:1052–9.
8. Miettinen KH, Eriksson S, Magga J, et al. Clinical significance of
troponin I efflux and troponin autoantibodies in patients with dilated
cardiomyopathy. J Card Fail 2008;14:481–8.Key Words: autoimmunity y biomarkers y heart failure y troponin.
